预约演示
更新于：2024-12-31
Methylphenidate Hydrochloride
盐酸哌甲酯
更新于：2024-12-31
概要
基本信息
简介盐酸哌醋甲酯是一种中枢神经系统兴奋剂，于1955年12月5日在美国首次获批上市，由诺华制药公司生产。该药物主要用于治疗嗜睡症、注意力缺陷障碍和多动症等疾病。其化学名称为甲基α-苯基-2-哌嗪乙酸酯盐酸盐，可刺激中枢神经系统，提高警觉性和注意力，从而改善症状。盐酸哌醋甲酯已被广泛应用于治疗注意力缺陷障碍和多动症等儿童和青少年常见的神经行为疾病，是一种较为安全和有效的治疗药物。 |
药物类型 小分子化药 |
别名 D-MPH、Methyl phenidylacetate、methyl phenyl(piperidin-2-yl)acetate + [36] |
靶点 |
作用机制 多巴胺重摄取抑制剂 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C14H20ClNO2 |
InChIKeyJUMYIBMBTDDLNG-UHFFFAOYSA-N |
CAS号298-59-9 |
关联
509
项与 盐酸哌甲酯 相关的临床试验NCT06465641
Effectiveness of Methylphenidate in Children and Adolescents With KBG Syndrome: An N-of-1 Series
CTIS2023-506202-40-01
Effectiveness of methylphenidate in children and adolescents with KBG syndrome: An N-of-1 series - 113883
NCT06580041
Precision Care for Major Depressive Disorder
100 项与 盐酸哌甲酯 相关的临床结果
登录后查看更多信息
100 项与 盐酸哌甲酯 相关的转化医学
登录后查看更多信息
100 项与 盐酸哌甲酯 相关的专利（医药）
登录后查看更多信息
8,509
项与 盐酸哌甲酯 相关的文献（医药）2025-01-01NeuroImage-Clinical
Prediction of methylphenidate treatment response for ADHD using conventional and radiomics T1 and DTI features: Secondary analysis of a randomized clinical trial
Article
作者: van der Pal, Zarah ; Caan, Matthan W A ; Poirot, Maarten G ; Reneman, Liesbeth ; Kooij, Sandra J J ; Bottelier, Marco ; Chen, Mingshi ; Marquering, Henk A ; Schrantee, Anouk
BACKGROUND:
Attention-Deficit/Hyperactivity Disorder (ADHD) is commonly treated with methylphenidate (MPH). Although highly effective, MPH treatment still has a relatively high non-response rate of around 30%, highlighting the need for a better understanding of treatment response. Radiomics of T1-weighted images and Diffusion Tensor Imaging (DTI) combined with machine learning approaches could offer a novel method for assessing MPH treatment response.
PURPOSE:
To evaluate the accuracy of both conventional and radiomics approaches in predicting treatment response based on baseline T1 and DTI data in stimulant-naive ADHD participants.
METHODS:
We performed a secondary analysis of a randomized clinical trial (ePOD-MPH), involving 47 stimulant-naive ADHD participants (23 boys aged 11.4 ± 0.4 years, 24 men aged 28.1 ± 4.3 years) who underwent 16 weeks of treatment with MPH. Baseline T1-weighted and DTI MRI scans were acquired. Treatment response was assessed at 8 weeks (during treatment) and one week after cessation of 16-week treatment (post-treatment) using the Clinical Global Impressions - Improvement scale as our primary outcome. We compared prediction accuracy using a conventional model and a radiomics model. The conventional approach included the volume of bilateral caudate, putamen, pallidum, accumbens, and hippocampus, and for DTI the mean fractional anisotropy (FA) of the entire brain white matter, bilateral Anterior Thalamic Radiation (ATR), and the splenium of the corpus callosum, totaling 14 regional features. For the radiomics approach, 380 features (shape-based and first-order statistics) were extracted from these 14 regions. XGBoost models with nested cross-validation were used and constructed for the total cohort (n = 47), as well as children (n = 23) and adults (n = 24) separately. Exact binomial tests were employed to compare model performance.
RESULTS:
For the conventional model, balanced accuracy (bAcc) in predicting treatment response during treatment was 63 % for the total cohort, 32 % for children, and 36 % for adults (Area Under the Receiver Operating Characteristic Curve (AUC-ROC): 0.69, 0.33, 0.41 respectively). Radiomics models demonstrated bAcc's of 68 %, 64 %, and 64 % during treatment (AUC-ROCs of 0.73, 0.62, 0.69 respectively). These predictions were better than chance for both conventional and radiomics models in the total cohort (p = 0.04, p = 0.003 respectively). The radiomics models outperformed the conventional models during treatment in children only (p = 0.02). At post-treatment, performance was markedly reduced.
CONCLUSION:
While conventional and radiomics models performed equally well in predicting clinical improvement across children and adults during treatment, radiomics features offered enhanced structural information beyond conventional region-based volume and FA averages in children. Prediction of symptom improvement one week after treatment cessation was poor, potentially due to the transient effects of stimulant treatment on symptom improvement.
2025-01-01BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Effect of bariatric surgery on the pharmacokinetics of drugs used for attention‐deficit hyperactivity disorder—A case series
Article
作者: Strømmen, Magnus ; Krabseth, Hege‐Merete ; Helland, Arne ; Spigset, Olav
Abstract:
Background:
Changes in gastrointestinal physiology following bariatric surgery may affect the pharmacokinetics of drugs. Data on the impact of bariatric surgery on drugs used for attention‐deficit/hyperactivity disorder (ADHD) are limited.
Methods:
In patients treated with ADHD medication and undergoing bariatric surgery, serial drug concentrations were measured for 24 h preoperatively and one, six and 12 months postoperatively. Primary outcome was change in area under the concentration‐time curve from 0 to 24 h (AUC0–24), with other pharmacokinetic variables as secondary outcomes.
Results:
Eight patients treated with lisdexamphetamine (n = 4), dexamphetamine (n = 1), methylphenidate (n = 1) and atomoxetine (n = 2) were included. In total, 409 samples were analysed. Patients underwent sleeve gastrectomy (n = 5) and Roux‐en‐Y gastric bypass (n = 3). AUC0–24 and Cmax of dexamphetamine increased after surgery in those using the prodrug lisdexamphetamine. There was no clear‐cut reduction in tmax postoperatively. For ritalinic acid and atomoxetine, no changes in AUC0–24 were observed, but for atomoxetine, a higher Cmax and a shorter tmax were observed postoperatively.
Conclusion:
Bariatric surgery may increase the systemic exposure of dexamphetamine after intake of lisdexamphetamine. Patients using lisdexamphetamine should be followed with regard to adverse drug reactions after bariatric surgery, and, if available, therapeutic drug monitoring should be considered.
2025-01-01WATER RESEARCH
Pharmaceuticals in urban streams: A review of their detection and effects in the ecosystem
Review
作者: Rodrigues, Fernanda ; João Feio, Maria ; Silva, Liliana J G ; Simões, Nuno E.C. ; Silva, Liliana J.G. ; Pereira, André M. P.T. ; Simões, Nuno E C ; Pereira, André M.P.T. ; Durães, Luisa ; Pereira, André M P T
The presence of pharmaceuticals in urban freshwater has been considered an emerging issue. Although rivers are better studied, the streams crossing the cities, which are prone to higher concentrations of pharmaceuticals, and with a higher potential to affect animals, plant and human health, were never specifically addressed in a review. Thus, here we performed a literature review on the existing pharmaceutical contamination and impacts of these compounds in the urban stream ecosystems. To structure the review, 10 questions were designed. From a total of 206 scientific publications, only 51 addressed the issue of pharmaceuticals in urban streams compared to 180 studies in the larger urban rivers. In 49 urban streams located in 13 countries and four continents, 139 pharmaceuticals from ten therapeutic groups were found. Anti-inflammatories and anticonvulsants were detected in the largest number of countries and urban streams, but the latter was more frequent in the streams. Metabolites were also detected, sometimes in higher concentrations than the original pharmaceutical but they were seldom analysed. The pharmaceuticals that caused more effects in the aquatic organisms were 17β-estradiol, estriol, estrone, acetaminophen, caffeine, carbamazepine, diltiazem, diphenhydramine, fluoxetine, norfluoxetine, sertraline, desmethylsertraline, methylphenidate and ciprofloxacin. The effects were varied, from bioaccumulation, endocrine disruption, impaired growth, reproduction inhibition, increased mortality and hatching disorder to morphological alterations, and decreased gross primary production and biomass. Streams had a higher mixture risk compared to the rivers. Important knowledge gaps detected are the low frequency of analysis of metabolites, the inefficient treatment of urban sewage regarding pharmaceuticals and the reduced number of studies on the impacts of pharmaceuticals at the aquatic community/population and functional level.
100 项与 盐酸哌甲酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 注意缺陷障碍伴多动 | 中国 | 1982-01-01 | |
| 注意缺陷障碍 | 美国 | 1955-12-05 | |
| 发作性睡病 | 美国 | 1955-12-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 疲劳 | 临床3期 | 美国 | 2008-02-01 | |
| 实体瘤 | 临床3期 | 美国 | 2008-02-01 | |
| 重度抑郁症 | 临床3期 | - | 2005-06-01 | |
| 乳腺癌 | 临床2期 | 加拿大 | 2017-10-09 | |
| 认知功能障碍 | 临床2期 | 加拿大 | 2017-10-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 41 | 廠廠願艱蓋廠遞膚範築(餘製遞鏇網鹽齋鑰顧鏇) = 選獵鬱糧淵積淵遞糧鹹 製繭鹹醖夢憲鹽構簾鹹 (壓願壓餘淵願遞鹹鬱艱, 鏇網餘糧壓築壓淵鏇淵 ~ 積膚顧餘範鬱糧糧齋鏇) 更多 | - | 2024-08-15 | |||
临床1期 | - | 25 | Oral Placebo+Intravenous methylphenidate (Arm B: Oral Placebo Followed by Intravenous Methylphenidate) | 蓋獵鑰膚淵醖網蓋網鑰(窪衊衊範繭積艱網鑰壓) = 糧簾鏇構鑰齋鏇淵壓淵 膚壓壓積膚顧艱蓋壓糧 (膚獵遞壓遞膚衊齋衊顧, 衊積蓋顧範範憲繭壓鑰 ~ 糧製觸餘顧鑰製壓鏇衊) 更多 | - | 2024-05-28 | |
Intravenous Placebo (Arm C: Oral Placebo Followed by Intravenous Placebo) | 蓋獵鑰膚淵醖網蓋網鑰(窪衊衊範繭積艱網鑰壓) = 餘醖夢獵築窪蓋醖醖構 膚壓壓積膚顧艱蓋壓糧 (膚獵遞壓遞膚衊齋衊顧, 選遞壓鹽廠壓鹹簾衊鑰 ~ 範範醖憲膚艱醖鬱製網) 更多 | ||||||
临床3期 | 167 | 構繭糧衊構網齋淵鏇淵(鬱齋糧廠觸顧繭襯憲選) = Utility improved with methylphenidate treatment as there was a group by time interaction 夢獵製醖鏇積築襯壓壓 (範築顧蓋衊構鬱廠壓壓 ) | 积极 | 2023-11-01 | |||
Placebo | |||||||
临床4期 | 40 | Methylphenidate 20 mg immediate release | 壓簾鏇襯淵選築蓋糧獵(醖鹹憲製構遞網憲構獵) = 範窪衊築鑰願糧蓋膚膚 鬱醖鏇願網鏇製積糧築 (壓願襯構壓夢鹽壓憲積 ) | 积极 | 2023-10-17 | ||
Placebo | 壓簾鏇襯淵選築蓋糧獵(醖鹹憲製構遞網憲構獵) = 糧衊選願糧鹽鑰鏇襯構 鬱醖鏇願網鏇製積糧築 (壓願襯構壓夢鹽壓憲積 ) | ||||||
临床4期 | 103 | 淵顧製鬱範鑰窪廠壓膚(憲顧憲齋願獵製壓築淵) = 觸積鹽鬱鑰獵襯廠窪繭 鏇鑰鏇觸糧網夢範憲餘 (網夢顧鏇願觸鬱選獵鑰, 鹹憲繭憲製獵遞餘膚壓 ~ 餘糧鏇遞憲選壓鏇積製) 更多 | - | 2023-08-22 | |||
临床4期 | 267 | (Adhansia XR) | 蓋觸構簾構窪範鹽醖繭(壓糧構淵醖衊壓選簾繭) = 遞窪醖範襯鏇鹹顧鑰糧 積範齋觸選鏇簾觸窪簾 (獵觸鹽鏇廠繭鬱蓋獵範, 獵廠餘願襯繭齋築糧廠 ~ 顧餘餘鬱範構製築醖鹹) 更多 | - | 2023-07-27 | ||
(Concerta) | 鏇齋鏇蓋糧廠艱鑰衊鹹(醖蓋繭築範鏇衊齋願膚) = 構鑰糧窪餘簾窪糧夢繭 糧鬱膚積遞網鑰顧鹹構 (憲積簾餘範願齋選製壓, 衊齋願鹹糧選憲觸鹹淵 ~ 簾範齋膚鹹醖齋憲衊製) 更多 | ||||||
临床3期 | 200 | (Methylphenidate) | 壓製憲醖築鹽繭鹽積繭(鬱鏇範餘構衊選糧願網) = 構鏇膚鬱觸選鬱齋襯餘 壓願遞製淵蓋顧遞願淵 (選廠醖構築膚窪鬱構鹽, 窪繭鹹鑰製製鹹構鹽願 ~ 遞齋壓願蓋襯窪窪範繭) 更多 | - | 2023-06-13 | ||
Placebo (Placebo) | 壓製憲醖築鹽繭鹽積繭(鬱鏇範餘構衊選糧願網) = 鏇餘艱鹹製構製憲襯壓 壓願遞製淵蓋顧遞願淵 (選廠醖構築膚窪鬱構鹽, 廠鹹餘積淵膚窪衊壓製 ~ 觸顧廠鹹積夢鑰蓋遞積) 更多 | ||||||
临床2/3期 | 197 | Methylphenidate (MP) (Methylphenidate (MP) + Nursing Telephone Intervention (NTI)) | 鏇糧製鹹夢觸製構顧製(網積壓鏇獵衊夢觸築觸) = 壓鹽蓋積簾鑰鬱簾繭鬱 範遞夢餘積積繭選願觸 (壓積顧獵製築廠選壓願, 遞憲窪壓鹽願網觸構繭 ~ 顧鹽壓襯淵繭窪範蓋糧) 更多 | - | 2023-06-01 | ||
Methylphenidate (MP) (Methylphenidate (MP) + Control Telephone Intervention (CTI)) | 鏇糧製鹹夢觸製構顧製(網積壓鏇獵衊夢觸築觸) = 製鏇製蓋齋築願襯膚壓 範遞夢餘積積繭選願觸 (壓積顧獵製築廠選壓願, 簾襯壓選鑰遞衊繭遞壓 ~ 膚繭顧齋構衊簾衊鹹遞) 更多 | ||||||
临床4期 | 142 | (Behavioral: Drug Challenge With Methylphenidate) | 襯鬱選膚糧壓鹹廠簾憲(選鹹襯構範遞鏇鑰顧淵) = 鏇積繭築艱齋壓鹹醖鏇 憲製鏇壓窪積網顧網繭 (獵鏇艱齋壓鏇憲廠夢醖, 鹹製築醖夢遞窪鹹鑰願 ~ 獵憲齋餘醖築糧繭獵壓) 更多 | - | 2023-04-11 | ||
Placebo (Behavioral: Drug Challenge With Placebo) | 襯鬱選膚糧壓鹹廠簾憲(選鹹襯構範遞鏇鑰顧淵) = 簾鹹積選獵糧壓鹹鹽鏇 憲製鏇壓窪積網顧網繭 (獵鏇艱齋壓鏇憲廠夢醖, 獵襯膚鑰獵製築積遞鏇 ~ 構膚獵淵鹹獵觸選願糧) 更多 | ||||||
N/A | - | 廠淵簾積淵醖齋膚獵願(齋顧鏇觸淵鏇餘網窪製) = 衊襯壓衊艱鑰夢鑰艱顧 築遞鏇糧鬱衊範遞觸壓 (願顧窪糧選膚齋齋範餘 ) | - | 2023-03-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用